Please use this identifier to cite or link to this item: https://dipositint.ub.edu/dspace/handle/2445/18651
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMitchell, S .A.cat
dc.contributor.authorGrove, J.cat
dc.contributor.authorSpurkland, A.cat
dc.contributor.authorBoberg, Kirsten M.cat
dc.contributor.authorFleming, K. A.cat
dc.contributor.authorDay, Christopher P.cat
dc.contributor.authorSchrumpf, E.cat
dc.contributor.authorChapman, Roger W.cat
dc.contributor.authorParés Darnaculleta, Albertcat
dc.contributor.authorCaballeria Rovira, Joancat
dc.contributor.authorRodés, J.cat
dc.date.accessioned2011-07-07T12:30:22Z-
dc.date.available2011-07-07T12:30:22Z-
dc.date.issued2001-
dc.identifier.issn0017-5749-
dc.identifier.urihttps://hdl.handle.net/2445/18651-
dc.description.abstractBACKGROUND AND AIMS Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. Abnormalities in immune regulation and genetic associations suggest that PSC is an immune mediated disease. Several polymorphisms within the tumour necrosis factor α (TNF-α) and interleukin 10 (IL-10) promoter genes have been described which influence expression of these cytokines. This study examines the possible association between polymorphisms at the −308 and −627 positions in the TNF-α and IL-10 promoter genes, respectively, and susceptibility to PSC. METHODS TNF-α −308 genotypes were studied by polymerase chain reaction (PCR) in 160 PSC patients from Norway and the UK compared with 145 ethnically matched controls. IL-10 −627 genotypes were studied by PCR in 90 PSC patients compared with 84 ethnically matched controls. RESULTS A total of 16% of Norwegian PSC patients and 12% of British PSC patients were homozygous for the TNF2 allele compared with 3% and 6% of respective controls. The TNF2 allele was present in 60% of PSC patients versus 30% of controls (ORcombined data=3.2 (95% confidence intervals (CI) 1.8–4.5); pcorr=10−5). The association between the TNF2 allele and susceptibility to PSC was independent of the presence of concurrent inflammatory bowel disease (IBD) in the PSC patients; 61% of PSC patients without IBD had TNF2 compared with 30% of controls (ORcombined data=3.2 (95% CI 1.2–9.0); pcorr=0.006 ). There was no difference in the −627 IL-10 polymorphism distributions between patients and controls in either population. The increase in TNF2 allele in PSC patients only occurs in the presence of DRB1*0301 (DR3) and B8. In the combined population data, DRB1*0301 showed a stronger association with susceptibility to PSC than both the TNF2 and B8 alleles (ORcombined data=3.8, pcorr=10−6 v ORcombined data=3.2, pcorr=10−5 vORcombined data =3.41, pcorr=10−4, respectively). CONCLUSIONS This study identified a significant association between possession of the TNF2 allele, a G→A substitution at position −308 in the TNF-α promoter, and susceptibility to PSC. This association was secondary to the association of PSC with the A1-B8-DRB1*0301-DQA1*0501-DQB1*0201 haplotype. No association was found between the IL-10 −627 promoter polymorphism and PSC.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoengeng
dc.publisherBMJ Groupeng
dc.relation.isformatofReproducció digital del document publicat a: http://dx.doi.org/10.1136/gut.49.2.288cat
dc.relation.ispartofGut, 2001, vol. 49, núm. 2, p. 288-294-
dc.relation.urihttp://dx.doi.org/10.1136/gut.49.2.288-
dc.rights(c) BMJ Publishing Group Ltd and British Society of Gastroenterology, 2001-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationGenètica mèdicacat
dc.subject.classificationColèdoccat
dc.subject.classificationCèl·lules cancerosescat
dc.subject.classificationNecrosicat
dc.subject.classificationCitoquinescat
dc.subject.otherMedical geneticseng
dc.subject.otherColedocuseng
dc.subject.otherCancer cellseng
dc.subject.otherNecrosiseng
dc.subject.otherCytokineseng
dc.titleAssociation of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitiseng
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec583543-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid11454808-
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
583543.pdf249.87 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.